Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome

Worster, Andrew; Devereaux, P. J.; Heels-Ansdell, Diane; Guyatt, Gordon H.; Opie, John; Mookadam, Farouk; Hill, Stephen A.
June 2005
CMAJ: Canadian Medical Association Journal;6/21/2005, Vol. 172 Issue 13, p1685
Academic Journal
Abstract Background Ischemia-modified albumin (IMA) has been suggested as a marker of cardiac ischemia. Little, however, is known about its capacity to predict short-term serious cardiac outcomes (death, myocardial infarction, congestive heart failure, serious arrhythmia, or refractory ischemic cardiac pain) in patients arriving at the emergency department with symptoms that may indicate cardiac ischemia. Methods We screened 546 patients over a 4-week period, of whom 189 fulfilled our entry criteria by presenting to an emergency department with potential cardiac-ischemia symptoms within 6 hours after chest pain, seeing an emergency physician who chose to order a troponin I test, and having no serious cardiac outcome before the troponin result became available. We followed the study patients for 72 hours to determine if any experienced a serious cardiac outcome. We calculated the likelihood ratios (LRs) of IMA findings predicting serious cardiac outcomes that could not be diagnosed at presentation with current techniques. Results Of the 189 patients, 24 had a serious cardiac outcome within 72 hours after their arrival at the emergency department. The likelihood ratios for IMA measurement within 6 hours after chest pain predicting a serious cardiac outcome within the next 72 hours were 1.35 (95% confidence interval [CI] 0.315-5.79) for IMA ≤ 80 U/mL and 0.98 (95% CI 0.86- 1.11) for IMA > 80 U/mL. Conclusions These data suggest that in patients presenting with chest pain who have not yet experienced a serious cardiac event, IMA is a poor predictor of serious cardiac outcomes in the short term.


Related Articles

  • When prognosis precedes diagnosis: putting the cart before the horse. Sabatine, Marc S. // CMAJ: Canadian Medical Association Journal;6/21/2005, Vol. 172 Issue 13, p1697 

    Comments on a study concerning the use of ischemia-modified albumin (IMA) as a biomarker for acute coronary syndrome. Overview of the study; Background on IMA.

  • Dual antiplatelet therapy fails to reduce CV event risk in high-risk patients.  // Formulary;May2006, Vol. 41 Issue 5, p237 

    The article presents a study from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization Management, and Avoidance that accounts on the failure of the clopidogrel to reduce the risk of cardiovascular events in stable aspirin-treated patients. The study also highlighted the...

  • Study Design in Dementia Drug Trials. MacKnight, Chris // Canadian Journal of Neurological Sciences;Mar2007 Supplement 1, Vol. 34, pS19 

    The article focuses on issues surrounding study design in drug trials for dementia in Canada. It is unlikely that a novel study design such as randomized start or withdrawal could provide convincing evidence of disease modification in the absence of an accepted biological marker of progression....

  • Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment. Anping Cai; Liwen Li; Ying Zhang; Yujin Mo; Weiyi Mai; Yingling Zhou // Disease Markers;2013, Vol. 35 Issue 5, p551 

    Atherosclerotic cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality worldwide, although optimal medical therapy has been prescribed for primary and secondary preventions. Residual cardiovascular risk for some population groups is still considerably high although...

  • March update.  // Update;Mar2007, Vol. 74 Issue 3, p8 

    The article focuses on the results of various medical researches. A research conducted in Great Britain revealed that passive smokers have elevated levels of cardiovascular disease biomarkers. Another research conducted in Great Britain revealed that even very low levels of alcohol consumption...

  • Prognostic significance of ischemia-modified albumin in acute ischemic stroke patients: A preliminary study. Nayak, Amit R.; Kashyap, Rajpal S.; Kabra, Dinesh; Purohit, Hemant J.; Taori, Girdhar M.; Daginawala, Hatim F. // Annals of Neurosciences;Jan2011, Vol. 18 Issue 1, p5 

    Background: Ischemia-modified albumin (IMA) is a sensitive marker of ischemic event. However, limited studies are available regarding role of IMA in acute ischemic stroke (AIS). Purpose: The aim of this study was to evaluate time course of IMA in AIS patient to validate its prognostic value....

  • Preconditioning Strategies for Kidney Ischemia Reperfusion Injury: Implications of the “Time-Window” in Remote Ischemic Preconditioning. Yoon, Young Eun; Lee, Kwang Suk; Choi, Kyung Hwa; Kim, Kwang Hyun; Yang, Seung Choul; Han, Woong Kyu // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Remote ischemic preconditioning (IP) is a potential renoprotective strategy. However, there has been no demonstrated result in large animals and the role of time window in remote IP remains to be defined. Using a single-kidney porcine model, we evaluated organ protective function of remote IP in...

  • Albumin Kinetics in Patients Undergoing Major Abdominal Surgery. Norberg, Åke; Rooyackers, Olav; Segersvärd, Ralf; Wernerman, Jan // PLoS ONE;8/27/2015, Vol. 10 Issue 8, p1 

    Background: The drop in plasma albumin concentration following surgical trauma is well known, but the temporal pattern of the detailed mechanisms behind are less well described. The aim of this explorative study was to assess changes in albumin synthesis and transcapillary escape rate (TER)...

  • THERAPEUTIC ANGIOGENESIS IN CARDIOVASCULAR DISEASE. Simons, Michael; Ware, J. Anthony // Nature Reviews Drug Discovery;Nov2003, Vol. 2 Issue 11, p1 

    Despite considerable progress in the management of ischaemic cardiovascular disease during the past three decades, there remains a significant population of patients who are not served well by current treatment approaches. Stimulating revascularization in ischaemic regions is an attractive novel...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics